Listen
MONOVER (iron isomaltoside 1000), injectable iron
HAEMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Jun 01 2017
Reason for request
Inclusion
No clinical benefit demonstrated when compared with other iron-containing medicinal products administered by injection
- MONOVER has a Marketing Authorisation in the treatment of iron deficiency anaemia when oral iron preparations are ineffective or cannot be used, or when there is a clinical need to quickly restore the iron reserves.
- MONOVER has a chemical structure (dextran-free iron) that allows administration of a single high dose of iron with no prior test.
- The way it is administered (rapid administration and high single dose) can have a positive impact on the organisation of care and the management of patients at the hospital (limits the number of injections and visits required for the correction of iron deficiency).
- MONOVER has not been compared with FERINJECT.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
